Oxidative and non-oxidative active turnover of genomic methylcytosine in distinct pluripotent states

Fabio Spada¹*, Sarah Schiffers¹, Angie Kirchner¹, Yingqian Zhang¹², Olesea Kosmatchev¹, Eva Korytiakova¹, René Rahimoff¹§, Charlotte Ebert, and Thomas Carell¹*

¹Department of Chemistry, Ludwig Maximilians University Munich and Center for Integrated Protein Science Munich (CIPSM)
²College of Chemistry, State Key Laboratory of Elemento-Organic Chemistry and Department of Chemical Biology, Nankai University, Tianjin, China
§Current addresses: R.R., Department of Chemistry, University of California, Berkeley, USA
*Corresponding authors: Fabio Spada fabio.spada@cup.lmu.de; Thomas Carell: Thomas.Carell@cup.lmu.de

Abstract

Epigenetic plasticity underpins cell potency, but the extent to which active turnover of DNA methylation contributes to such plasticity is not known and the underlying pathways are poorly understood. Here we use mass spectrometry in combination with isotope tracing to quantitatively address the global turnover of genomic methylcytidine (mdC), hydroxymethylcytidine (hmdC) and formylcytidine (fdC) across mouse pluripotent cell states. High rates of mdC/hmdC oxidation and fdC turnover characterize a formative-like pluripotent state. In primed pluripotent cells the global mdC turnover rate is about 3-6% faster than can be explained by passive dilution through DNA synthesis. While this active component is largely dependent on Tet-mediated mdC oxidation, we also unveiled an additional mdC oxidation-independent turnover process based on DNA repair. This process accelerates upon acquisition of primed pluripotency and returns to low levels in lineage committed cells. Thus, in pluripotent cells active mdC turnover involves both mdC oxidation-dependent and -independent processes.
Introduction

Methylation at position 5 of deoxycytidine (dC) is the most prominent post-replicative nucleobase modification in higher eukaryotic genomes and its functional relevance has been extensively investigated\(^1,2\). In mammals, genomic dC is methylated to 5-methylcytidine (mdC) by the C5-DNA methyltransferases DNMT1, DNMT3a and DNMT3b\(^3\), mostly, but not exclusively in the context of CpG dinucleotides\(^4\). These enzymes differentially contribute to establishing and maintaining genomic mdC patterns across cellular and organismal generations. In addition, genomic mdC can be further modified by iterative oxidation to hydroxymethyl-, formyl- and carboxyl-dC (hmdC, fdC and cadC, respectively) through the action of Ten-Eleven Translocation (TET) di-oxygenases\(^5-7\). As several classes of DNA binding factors display differential affinity for their target sequences depending on the dC modification state\(^2,1,8\), genomic patterns of dC modification contribute to consolidation and propagation of gene expression states and chromatin structure, thus affecting fundamental processes such as cell fate determination and restriction, imprinting, X chromosome inactivation and genome stability\(^1,2\).

In the last two decades methylation of genomic dC was shown to be rapidly removed in various biological contexts\(^9,10\). Several erasure mechanisms were proposed, including prevention of methylation maintenance, which results in passive dilution of the modified base through DNA replication, and active demethylation by enzymatic processes\(^9,10\) (Fig. 1a). Among the latter oxidation of mdC to fdC or cadC by TET enzymes followed by base excision repair (BER) mediated by the DNA glycosylases TDG\(^9-11\) and Neil1/2\(^12,13\) is best characterized. Additional proposals invoke the involvement of other DNA repair pathways\(^10,14\) or direct C-C bond cleavage\(^15-18\). A third line of proposal posits that genomic mdC and hmdC could be deaminated to thymidine (dT) and hydroxymethyluridine (hmdU), respectively, either by a cytosine deaminase of the AID/APOBEC family\(^9,10\) or by de novo DNA methyltransferases DNMT3a/b\(^19\). The resulting T:G or hmU:G mismatches would be then resolved by BER or non-canonical mismatch repair (ncMMR)\(^20-23\). Finally, it was suggested that unmodified dC could be deaminated by AID and that long patch BER or ncMMR could lead to indirect co-removal of adjacent mC residues\(^22-24\). Currently, all these pathways are highly controversial, as there is no conclusive evidence for their functional relevance in vivo\(^9,10\). It is however conceivable that different pathways operate at different stages during development.

During early embryonic development, the epiblast transits through a spectrum of pluripotent states\(^25\). This transition can be modelled by cultivating mouse pluripotent stem cells (mPSCs) under specific conditions and involves dynamic changes in expression and
epigenetic landscapes, including a major global gain of mdC\textsuperscript{1,25}. Conversely, reversion from partially and heterogeneously primed mPSC cultures\textsuperscript{26} to the naïve state involves downregulation of \textit{de novo} methyltransferases and collapse of DNA methylation maintenance with consequent global and passive (Tet enzyme-independent) loss of genomic methylation\textsuperscript{27,28}. In contrast, little is known about the extent and nature of the turnover of modified genomic cytosines during the forward, developmentally relevant transition from naïve to primed pluripotent states. Here, we used metabolic labelling with stable isotope standards for highly accurate mass spectrometry based quantification of the global genomic mdC, hmdC and fdC turnover through a progression of pluripotent states. We show that upon acquisition of primed pluripotency roughly 3-6\% of the methylome is actively turned over. Most of this active turnover is due to Tet-mediated mdC oxidation, while a minor part involves an unknown mdC oxidation-independent DNA repair process.

\section*{Results}

\textbf{Global genomic mdC oxidation kinetics decrease upon progression to primed pluripotency.}

We cultured of mPSCs under specific conditions to model the progression of the embryonic epiblast from naïve to primed pluripotency and investigate the kinetics and turnover of dC modification during this transition. In order to monitor priming conditions, we first made use of a mPSC line expressing an Oct4-YFP reporter\textsuperscript{29}. After adaptation to naïve conditions in the presence of Gsk3 inhibitor CHIR99021 (CHIR), Mek1/2 inhibitor PD0325901 (also known as 2i) and LIF, the cells were plated at low density in basal medium containing CHIR and the Tankyrase inhibitor IWR1-endo as previously described\textsuperscript{30}. Live cell microscopy over the course of 6 days without passaging showed that these cells rapidly formed monolayer colonies with remarkably homogeneous nuclear YFP signal across the culture (Supplementary Fig. S1a), confirming that under these conditions mPSC cultures progress to a primed state synchronously without apparent loss of pluripotency. Similarly intense and homogeneous YFP signals were observed when the same reporter line was permanently primed to mouse Epiblast Stem Cells (mEpiSCs) in serum-free, chemically defined medium supplemented with CHIR, IWR1, FGF-2 and Activin A (Supplementary Fig. S1b). We then used ultra-high pressure liquid chromatography coupled with triple quadrupole mass spectrometry (UHPLC-MS\textsuperscript{3})\textsuperscript{31} to analyse global levels of genomic mdC and hmdC upon priming of mPSCs under the same conditions over a five day time course. As previously reported\textsuperscript{32}, the transition from the naïve (2i/LIF) to a homogeneously primed pluripotent state was marked by a large increase in global levels of genomic mdC, while hmdC abundance
dropped sharply, both modifications reaching plateau levels by day 4 (Supplementary Fig. S1c). Similar global levels of genomic mdC and hmdC were detected in the Oct4-YFP reporter mouse epiblast stem cells (mEpiSCs) derived and stably maintained under serum-free conditions, excluding potential confounding effects of undefined serum composition. Note that under both serum-containing and serum-free conditions we avoided supplementation with ascorbic acid, which was shown to greatly increase the levels of oxidized mdC derivatives\textsuperscript{33}. The decrease in hmdC abundance upon priming is consistent with a recent proteomic analysis showing that the levels of chromatin bound Tet1 and 2 proteins are markedly reduced in mEpiSCs compared to naïve mPSCs, while Tet3 protein is undetectable in both states\textsuperscript{34}.

Notably, under 2i/LIF conditions, mPSCs exhibit low levels of genomic cytosine modification, loose imprinted methylation and are prone to genetic instability\textsuperscript{35,36}. In contrast, replacement of the Mek inhibitor with the Src inhibitor CGP77675 (conditions referred to as alternative 2i or a2i) results in relatively high genomic mdC levels as well as stable imprinted methylation and karyotype even upon prolonged culture. Nevertheless, gene expression patterns remain similar and developmental potential unaltered relative to those of naïve mPSCs (Ref.s 35, 36 and Fig. 1). At least as far as their methylome is concerned, mPSCs under a2i/LIF conditions fulfill the characteristics of the formative pluripotent state, an intermediate state during which competence for multi-lineage commitment is acquired\textsuperscript{37}. Therefore, the a2i/LIF and CHIR/IWR1 conditions allow comparison of genomic cytosine modification dynamics between functionally distinct pluripotent cell states with substantial and comparable steady state levels of genomic mdC. We then adopted a2i/LIF conditions both for routine mPSC maintenance and as starting state for further time course analyses of mPSC priming.

We then set out to monitor global cytosine modification kinetics during acquisition of primed pluripotency by metabolic labelling of the C5 substituent. To this aim we supplemented L-Methionine (Met)-free medium with isotopically labelled Met (m+4Met), whereby the methyl group provides a mass shift of four units ([\textit{methyl}\textsuperscript{13}C\textsubscript{5},\textsubscript{d}3], hereafter referred to as m+4). As for naturally occurring Met, m+4Met is incorporated into S-adenosylmethionine (SAM) and m+4 is transferred thereof onto genomic dC by Dnmts, generating m+4dC. The latter can be sequentially oxidised by Tet proteins to hm+3dC, f+2dC and ca+1dC (Fig. 1a)\textsuperscript{31}.

In order to attain accurate quantification of both naturally occurring (mdC, hmdC, fdC) and heavy (m+4dC, hm+3dC, f+2dC) isotopologues, we synthesised an even heavier series of corresponding isotopologues ([d\textsubscript{4},\textsuperscript{15}N\textsubscript{2}]-mdC, [\textsuperscript{13}C\textsubscript{5},\textsuperscript{15}N\textsubscript{2}]-hmdC and [\textsuperscript{13}C\textsubscript{5},\textsuperscript{15}N\textsubscript{2}]-fdC; Fig. 1b) and used them as internal standards for quantification by UHPLC-MS\textsuperscript{3}. In this work cadC and ca+1dC were not considered as isotopologues differing by only one mass unit cannot be reliably discriminated using UHPLC-MS\textsuperscript{3}. We first compared the modification
kinetics in cultures maintained constantly under a2i/LIF conditions to cultures undergoing priming in CHIR/IWR1 medium. In both cases we performed time course analyses over 2 days of labelling in the presence of m+4Met, which in the case of priming cultures was from day 3 to day 5 after transfer to CHIR/IWR1 medium (Fig.s 1c,d, Supplementary Fig. S2). Relative to a2i/LIF conditions, in priming cultures the global kinetics of dC methylation (m+4dC accumulation) were slightly faster, while the rate of m+4dC oxidation to hm+3dC was clearly slower. Accumulation of the further oxidized state f+2dC became undetectable under these conditions. Thus, the transition to primed pluripotency determines a major decrease in global oxidation of genomic mdC, which is consistent with the drastically reduced steady state levels of genomic hmdC (Supplementary Fig. S1) and with a recent report of lower levels of chromatin bound Tet proteins in primed cultures.

An active and largely Tet enzyme-dependent component of genomic mdC turnover in primed pluripotent cells

To monitor the turnover of modified genomic cytosines we reversed the labelling schema described above. We first pulsed labelled cultures with m+4Met, then chased the label for two days by transferring the cultures to medium with naturally occurring Met and collected samples every 12 h during the chase (Fig. 2a). We again compared cultures maintained constantly under serum/a2i/LIF conditions to cultures undergoing priming in serum/CHIR/IWR1 medium. In both cases the cultures were pulsed for five days with m+4Met before chasing. In the case of the primed cultures the first two pulse days were in a2i/LIF medium, while the last three were in CHIR/IWR1 medium, thus corresponding to the first three days of priming. To generate a reference for passive dilution of a genomic nucleoside through DNA synthesis, we co-pulsed with an isotopically labelled 2’-deoxythymidine having a mass shift of 12 units ([^15N₂,^13C₁₀]-dT; hereafter referred to as dT+12; Fig. 2a). Due to its highly efficient incorporation, dT+12 was co-pulsed only during the last day of the m+4Met pulse. Thereafter, dT+12 was chased for two days in parallel to m+4Met. Remarkably, while in most cases the levels of modified cytosines readily declined with the onset of the chase, under a2i/LIF conditions hm+3dC and f+2dC accumulated for the first 12 and 24 hours, respectively (Fig. 2b). This shows again that the rate of Tet-mediated oxidation is quite high in mPSCs under a2i/LIF conditions and declines sharply upon priming, as already seen with the time course analysis during m+4Met labelling (Fig. 1b,c). Notably, under a2i/LIF conditions the decline of f+2dC after 36 h became quite steep, pointing to high turnover of fdC. Although under priming conditions oxidation of mdC to hmdC and further to fdC was hardly detectable in labelling time course experiments (Fig. 1), the fact that in the pulse chase experiments the decline of labelled hmdC and fdC was
slower than that of dT+12 clearly shows that some mdC and hmdC oxidation still takes place (Fig 2b, central panel). Importantly, upon priming, the turnover of m+4dC is faster than the dilution rate of dT+12 (Fig. 2b, inset), revealing the presence of a component of the m+4dC turnover that cannot be explained by passive dilution through DNA synthesis. To assess the contribution of Tet-dependent oxidation to this component we performed the same pulse/chase experiment under priming condition (Fig. 2a lower part) with E14tg2a mPSCs lacking all three Tet proteins (Tet triple knockout, alias Tet TKO) as well as parental, Tet 1-3 proficient E14tg2a cells (Fig. 3; note that E14tg2a cells are Hprt null). In the parental cell line (Tet1-3 proficient), turnover of genomic m+4dC was again clearly faster than passive dilution of dT+12. After averaging the data from three such pulse chase experiments with wt mPSC lines, a paired two-tailed T-test showed high significance ($P=0.0053$) for the deviation between m+4dC and dT+12 decay rates. This accounts for an active component of global mdC turnover involving 3-6% of the methylome, depending on the time point (Fig. 2c). In contrast, in the genome of Tet TKO cells the decline rate of m+4dC was essentially indistinguishable from that of dT+12 (Fig. 3). This shows that the active component of the mdC turnover is indeed largely dependent on the presence of Tet enzymes, and thus mostly due to mdC oxidation.

**Deamination of mdC to dT**

Next to oxidative mdC turnover, we started to investigate a potential deamination based pathway. Deamination of mdC and hmdC to dT (mdU) and hmdU, respectively, has been proposed as a potential alternative first step for active erasure of genomic C methylation. Upon metabolic labelling with m+4Met, deamination of m+4dC would generate m+4dU, that is dT bearing the m+4 methyl group (Fig. 1a). In order to investigate this process quantitatively we synthesised the isotopologue dT-$[^{13}C_5,^{15}N_2]$ (Fig. 1b) and used it as a standard for UHPLC-MS analysis. As the source of methyl group for de novo dT biosynthesis is serine through 5,10-methylenetetrahydrofolate and not methionine through SAM, it is expected that, upon supplementation of the medium with m+4Met, m+4dC is the only source of m+4dU. To verify this expectation, we made use of mPSCs lacking all catalytically active Dnmts (Dnmt TKO), and therefore devoid of genomic mdC. After priming in the presence of m+4Met, m+4dU was clearly detected in the genome of parental wt J1 mPSCs, but not in Dnmt TKO cultures. Thus, generation of m+4dU strictly requires the presence of m+4dC, showing that m+4dU originates exclusively through deamination of m+4dC (Supplementary Fig. S3).
Direct deamination of genomic mdC would imply the formation of T:G mismatches, which, if not efficiently repaired, would be highly mutagenic. It would then be reasonable to expect that a mechanism for highly efficient coupling of mdC deamination with BER of the ensuing T:G mismatches would have co-evolved so as to minimize the steady state levels of such mismatches. In contrast to this idea, we surprisingly detected substantial accumulation of m+4dU in genomic DNA, whenever cultures were provided with m+4Met (gDNA; Fig. 1-5, Supplementary Fig. S3, S6). To explain this observation we considered an alternative scenario whereby genomic strands containing m+4dC may first be subject to a DNA repair process leading to the release of soluble m+4dC/m+4dCMP, either by direct exonuclease action, as upon MMR and end resection of double strand breaks, or through digestion of excised strands (e.g., in nucleotide excision repair). Deamination of this material by Cytidine and Deoxycytidylate deaminases (Cda and Dctd), would generate soluble m+4dU/m+4dUMP, which could be phosphorylated and re-incorporated into the genome through DNA synthesis (Fig. 4a). To test if the high levels of m+4dU detected in the genome are generated along this pathway, we supplemented the medium with m+4Met and increasing concentrations of unlabelled dT. If DNA repair generates soluble m+4dU/m+4dUMP, incorporation of the latter into gDNA will be outcompeted by unlabelled dT. In addition, a dT excess will lead to high concentrations of dTMP and dTTP, which are both known to feedback negatively on Dctd through product inhibition and allosteric regulation, respectively. The accumulation of genomic m+4dU in priming mPSC cultures was indeed progressively reduced with supplementation of increasing concentrations of unlabelled dT (Fig. 4b). This result supports the idea that genomic m+4dU originates in large part from a pool of soluble precursor.

To further probe whether deamination of m+4dC takes place within gDNA or at the level of soluble nucleoside/nucleotide pools, we next used CRISPR/Cas9-mediated gene editing to generate mPSC with double deficiency for Cda and Dctd (CD-DKO; Supplementary Fig. 4a,b). Genomic sequencing showed that three of the isolated clonal lines bear compound biallelic Cda and Dctd mutations incompatible with the expression of functional enzymes (Supplementary Fig S4c-e). All three CD-DKO clones grew at slower rates than parental wt cells, a phenotype which was at least partially relieved by supplementation of the medium with dT (Supplementary Fig. S4f). This indicates that deamination of (d)C/(d)CMP by Cda and/or Dctd provides substantial amounts of (d)U/(d)UMP for biosynthesis of (d)T/(d)TMP by Thymidine synthase to support DNA replication and is fully consistent with previously reported dT auxotrophy of Dctd deficient somatic cell lines. As two of the CD-DKO clones grew particularly poorly under serum/CHIR/IWR1 priming conditions, we first used serum/LIF medium for metabolic labelling with m+4Met under priming conditions. Importantly, while the
Spada et al.

The genomic content of mdC/m+4dC was the same as in parental wt J1 cells, only background levels of m+4dU could be measured in all three CD-DKO clones (Fig 4c). The same result was obtained with CD-DKO clone 40 upon priming in serum/CHIR/IWR1 medium (Fig. 4d). These results clearly show that the genomic m+4dU measurable in wt cells with our UHPLC-MS/MS method originates from a process involving direct repair of gDNA containing m+4dC, with consequent release of soluble m+4dC/m+4dCMP, followed by deamination to m+4dU/m+4dUMP and (re)-incorporation of the latter into the genome through phosphorylation to the triphosphate state and DNA synthesis. Although our data point to exclusive deamination in the soluble pool, we wanted to further investigate potential deamination events of mdC to T directly in the genome, particularly in light of previous reports in this direction\textsuperscript{19,21}. In this respect it is important to consider the limitations of our quantitative UHPLC-MS\textsuperscript{3} method. In UHPLC the overwhelming amount of natural dT present in the genome co-elutes with m+4dU and potentially outcompetes it during ionization for the capture of charge. The effect is a strong ion suppression, resulting in a reduction of the m+4dU signal and, consequently, a high limit of detection (LOD). To put this effect into perspective we calculated that our LOD for m+4dU is about 100 times higher than that for fdC (around 1x10\textsuperscript{-5} versus 1x10\textsuperscript{-7} per nucleotide), which is a relatively stable dC modification considered to have an epigenetically relevant role.

However, deamination of very few m+4dC residues directly within the genome could trigger long patch BER and MMR\textsuperscript{22,23}, leading to the release of much larger amounts of m+4dC in the soluble pool and, subsequently, deamination to m+4dU and re-incorporation into the genome, explaining the large amounts of genomic m+4dU observed. In CD-DKO cells direct deamination of genomic m+4dC would be expected to be the only potential source of m+4dU and, as the latter would then be mismatched to G, its steady state levels would be expected to be very low due to efficient repair. In order to probe genomic deamination with higher sensitivity the ion suppression effect had to be substantially reduced. To this end we performed a double labelling experiment with m+4Met and a dC nucleoside where 9 hydrogen atoms are replaced with deuterium (dC[D\textsubscript{9}]; Supplementary Fig. S5a). After incorporation into the genome, dC[D\textsubscript{9}] will be methylated to m+4dC[D\textsubscript{8}], which deaminates to m+4dU[D\textsubscript{8}] (a dT with eleven D atoms and a +12 mass shift; Supplementary Fig S5a). This massive H-to-D exchange was chosen as it is known to determine a shift to shorter retention time in UHPLC, allowing m+4dU[D\textsubscript{8}] to escape co-elution with dT. Indeed, co-injection tests showed a slightly shorter retention time for dT[D\textsubscript{8}] relative to dT (Supplementary Fig S5b). Notably, m+4dU[D\textsubscript{8}] is expected to have an even shorter retention time that would allow it to at least partly escape ion suppression from natural dT. After double labelling with m+4Met and dC[D\textsubscript{9}] we were able to detect m+4dU[D\textsubscript{8}] confidently only in wt mPSCs (Supplementary
However, we sporadically detected small m+4dU[De] peaks in technical replicates of CD-DKO samples. After integration of these sporadic signals, the corresponding values were invariably below LOD, defined as three times the average level of blank samples. Although we cannot exclude that these signals are caused by background processes, we nevertheless performed a calculation taking into account the limits of detection and quantification that were gained by deuterium labelling. This calculation allows us to estimate the maximum number of potential genomic deamination events between 500 and 5000 m+4dU[De] molecules per cell in the course of our labelling experiment. According to an estimated rate constant for spontaneous hydrolytic deamination of mdC in solution only around 20 such events would be expected to take place. Therefore, although a reliable and reproducible signal for m+4dU[De] could not be detected in CD-DKO cells, we cannot exclude the occurrence of genomic deamination above the rates of spontaneous hydrolysis. However, in the best case this process cannot exceed a level of 1x10^-6-1x10^-7 events per nucleotide.

Oxidation-independent repair of mdC-containing gDNA is developmentally regulated

To investigate whether oxidation-independent mdC turnover is regulated during the transition to primed pluripotency, we first compared the genomic abundance of m+4dU in the time course and pulse-chase experiments under naïve and priming conditions described above (Fig. 1-3, Supplementary Fig. S2). In time course experiments, progressive accumulation m+4dU was much faster under priming conditions, reaching approximately five times higher levels than under naïve conditions (Fig. 1, Supplementary Fig. S3). Also, m+4dU was the only m+4dC derivative that accumulated during label chase under priming conditions, though to different extents in the two cell lines tested (Fig. 2b,3). Thus, in contrast with the observed decline of mdC oxidation (Fig. 1,2, Supplementary Fig. S3), these results reveal increased rates of oxidation-independent repair of mdC-containing gDNA upon acquisition of primed pluripotency. This anti-correlation suggests that oxidation-independent mdC turnover through DNA repair may serve at least in part as a supplementary pathway for the erasure of dC methylation. However, as in primed Tet TKO mPSCs there was no apparent difference between global mdC turnover and passive dilution through DNA synthesis (Fig. 3: decay of m+4dC and dT+12, respectively), this process cannot involve more than 1% of the methylome.

At last, we compared oxidation-independent mdC turnover through DNA repair in pluripotent states (naïve serum/a2i/LF and primed serum/CHIR/IWR1 and CDM/CHIR/IWR1/FGF-2/Activin A) with various lineage committed cell types, including primary and immortalized
embryonic fibroblasts, neural stem cells (NSCs) and HeLa cells. Although primed pluripotent cells were labelled with m+4Met for only two to three days, m+4dU reached higher levels in their genome than in those of any of the somatic cell types cultured for variable, but substantially longer periods, ranging from 6 to 12 days (Fig. 5a). This clearly shows that in lineage committed cells oxidation-independent mdC turnover through DNA repair is substantially lower than in primed pluripotent cells. In addition, the rate of oxidation-independent mdC turnover is clearly not proportional to the global genomic abundance of mdC either between pluripotent states or among pluripotent and lineage committed cells. In particular, among the latter oxidation-independent mdC turnover is clearly more active in NSCs than in fibroblasts, despite the mdC genomic content being at least 20% lower in NSCs. These observations indicate that oxidation-independent mdC turnover is under developmental and cell lineage-dependent control.

Discussion

Recent methylome analysis of matched clonal and polyclonal cell populations\textsuperscript{45} and studies on the contribution of Dnmt3 proteins to DNA methylation maintenance\textsuperscript{46,47} suggested that in heterogeneously primed mPSCs cultures (serum/LIF) genomic mdC undergoes higher dynamic turnover as compared to differentiated somatic cells. However, the extent and especially the nature of this turnover have not been addressed. Previously, Bachmann \textit{et al.} reported pulse-chase experiments with m+4Met to estimate the global turnover of genomic dC modifications in mPSCs cultured under naïve conditions (2i/LIF), using a very short pulse time\textsuperscript{48,49}. However, the naïve pluripotent state is characterised by very low global levels of genomic dC modifications, which increase only upon exit from the naïve state and acquisition of primed pluripotency\textsuperscript{1,25}, a crucial transition to lay the ground for commitment to somatic lineages.

Here, we report the first analysis of on- and off-rate kinetics for genomic dC modifications upon transition to primed pluripotency. We show that under a2i/LIF conditions the rates of mdC oxidation to hmdC and further to fdC are quite sustained and the removal/conversion of fdC is very rapid. This points to a very dynamic equilibrium for fdC under these conditions. In contrast, upon transition to primed pluripotency the global oxidation rates of mdC and hmdC as well as the removal of hmdC and fdC decline drastically. Despite this the global turnover rate of genomic mdC is 3-6% faster than can be accounted for by passive dilution through DNA synthesis (DNA replication and repair; Fig. 5b) and this difference is largely due to Tet-mediated mC oxidation. Evidence for passive erasure of dC methylation based on impairment of its maintenance has been provided for primordial germ cells, preimplantation embryonic development\textsuperscript{1,25} and the reversion from partially primed/formative states present
in serum/LIF cultures to the naïve pluripotent state\textsuperscript{28}. We suggest that against the backdrop of global gain and maintenance of dC methylation occurring in the forward developmental transition from naïve to primed pluripotency an active demethylation mechanism may be more attainable than preventing maintenance of dC methylation at selected sites, especially in the case of loci with a readily accessible chromatin configuration like actively transcribed genes.

Furthermore, by tracking the conversion of m+4dC into m+4dU we show that a small part of genomic cytosine methylation is turned over by a DNA repair process that involves direct excision of mdC from the genome (Fig. 5b). Although the nature of this DNA repair process remains to be determined, its rate is not proportional to global genomic mdC levels, either between pluripotent states or lineage committed cells, indicating that the underlying DNA repair process is developmentally regulated. In this regard, it should be noted that the expression of DNA repair factors and the proficiency of various DNA repair pathways were shown to be higher in PSCs, including primed human PSCs, than in somatic cells\textsuperscript{50–52}. Interestingly, the levels of oxidation-independent mdC turnover show an inverse correlation with mdC oxidation rates across pluripotent states, hinting at a possible function as alternative or supplementary mechanism dedicated to active erasure of cytosine methylation. Whether this is indeed the case requires further investigation.

**Methods**

**Cell culture**

Medium components were from Sigma unless specified otherwise. Basal medium for mPSC culture was DMEM high glucose containing 10% FBS (Pan-ES, Pan-Biotech), 2 mM L-Alanyl-L-Glutamine, 1x MEM Non-essential Amino Acid Solution and 0.1 mM β- mercaptoethanol. mPSC lines were routinely maintained in basal medium supplemented with 1000 U/mL LIF (ORF Genetics), 3 µM CHIR99021 and 7.5 µM CGP77675 (a2i). For adaptation to 2i/LIF conditions CGP was replaced with 1 µM PD0325901. For priming, mPSC basal medium was supplemented with 1.5 µM CHIR99021 and IWR1-end at 2.5 µM as previously reported\textsuperscript{53}. For experiments under serum/LIF conditions basal medium was supplemented exclusively with 1000 U/ml LIF. Small molecule inhibitors were purchased from Selleckchem (CHIR, PD, IWR1), Axon Medchem (CHIR, CGP, PD, IWR1) or MedChemExpress (CHIR). Gelatin coating was used for all mPSCs cultures in serum containing medium, except for PR8 cultures where coating with 2.2 µg/cm\textsuperscript{2} Laminin 521 (BioLamina) was necessary. For metabolic labelling experiments with m+4Met under all conditions mPSC basal medium was generated with 0.2 mM L-Methionine- and L-Cysteine-
free DMEM (Sigma or Life Technologies) supplemented with m+4Met ([methyl-\textsuperscript{13}C,d\textsubscript{3}]) and L-Cysteine. EpiSCs in chemically defined serum-free medium (CDM) were derived from the Oct4-YFP reporter mPSC line OLY2-1\textsuperscript{29}. These were first adapted to CDM supplemented with CHIR, PD and LIF as reported above, then transferred to CDM supplemented with CHIR, CGP, 12 ng/ml FGF-2 (Miltenyi Biotec) and 20 ng/ml Activin A (PeproTec) and maintained in the latter medium by passaging as small cell clusters using 5 mM EDTA in Hank’s balanced salt solution without Mg\textsuperscript{2+}, Ca\textsuperscript{2+} and sodium carbonate supplemented with 10 mM HEPES buffer. CDM was DMEM high glucose supplemented with 1x NEAA, 2 mM L-Alanyl-L-Glutamine, 15 µg/ml human recombinant Insulin, 10 µg/ml human holo-Transferrin (Merck), 12.5 mg/ml AlbuMAX I (Life Technologies) 0.7 µg/ml vitamin B12, 1.8 ng/ml biotin, 0.75 µM ZnSO\textsubscript{4} and 2.6 nM CuSO\textsubscript{4}. Laminin 521 coating was used for all mPSC cultures in CDM. The neural stem cell line ENC1 was generated and cultured as previously described\textsuperscript{54}. ENC1 cells were labelled with m+4Met ([methyl-\textsuperscript{13}C,d\textsubscript{3}]) in DMEM/F-12 generated with L-Methionine-free DMEM supplemented with N2 \textsuperscript{55} and 20 ng/ml each of FGF-2 and EGF (PerpoTech). Primary mEFs (CF-1, Applied StemCell) were cultured in mPSC basal medium. Somatic cell lines were cultured in DMEM containing 10% FBS (Life Technologies), 2 mM L-glutamine and 0.1 mM β-mercaptoethanol.

**Generation of CD-DKO mPSCs by CRISPR/Cas9 editing**

Single guide RNAs were designed over exon1 and 4 of Cda and Dctd, respectively (Fig. S4), using CRISPR Design Tool (http://crispr.mit.edu/). The following oligonucleotides were used for construction of Cas9/gRNA expression vectors:

- mCda gRNA F: CACCGAOGAGCCGCTGGACGTGCTC
- mCda gRNA R: AAACGAGCACGTCCAGCGGCTGCTC
- mDctd gRNA F: CACCGACATTCGTTACACGGGAACA
- mDctd gRNA R: AAACTGTTCCCGTGTAACGAATGTC

The oligonucleotides were annealed and cloned in the BbsI site of pSpCas9-2A-Puro (PX 459; Addgene Plasmid 48139)\textsuperscript{56}. Cas9/gRNA expression vectors targeting both Cda and Dctd were co-transfected in wt J1 mPSCs using Lipofectamine 2000 (Life Technology) according to the manufacturer’s instructions. Two days after transfection cultures were selected with 1 µg/ml puromycin for two days and subcloned by limiting dilution. Clones were screened using the Surveyor Mutation Detection Kit (Transgenomics) and potential compound biallelically targeted clones were subject to sequencing.

For reverse transcription-PCR, RNA was isolated with the ZR-Duet DNA/RNA MiniPrep Kit (Zymo Research) and first strand cDNA synthesis was as previously described\textsuperscript{57}. The following primers were used to amplify Cda cDNA:
mCda F: AAGGCCATCTCCGAAGGGTA
mCda R: TCTTCAGGTCCAAACGAGGC
For western blot analysis of Dctd whole cell extracts and purified human recombinant DCTD protein\textsuperscript{58} were probed with a rabbit anti-DCTD antibody\textsuperscript{42}.

**Isolation of genomic DNA and UHPLC-MS/MS analysis**
Isolation, digestion and UHPLC-MS/MS analysis of gDNA samples were performed as described in Traube et al.\textsuperscript{59} with the following modifications: for every technical replicate 4 µg of gDNA were digested and analysed; the enzyme mixture including S1 Nuclease, Antarctic Phosphatase and snake venom Phosphodiesterase was used for digestion; the digestion mixture was supplemented with 0.8 µM Tetrahydrouridine (Abcam) to inhibit potential cytidine deaminase activity in enzyme preparations.

**Chemical synthesis**
For a description of the synthesis of labelled nucleosides see Supplementary Methods in Supplementary Information file.

**Methods-specific references**
53. Zhou, X., Chadarevian, J. P., Ruiz, B. & Ying, Q.-L. Cytoplasmic and Nuclear TAZ Exert Distinct Functions in Regulating Primed Pluripotency. *Stem Cell Reports* 9, 732–741 (2017).
54. Liu, N. *et al.* Intrinsic and Extrinsic Connections of Tet3 Dioxygenase with CXXC Zinc Finger Modules. *PLoS ONE* 8, e62755 (2013).
55. Nichols, J. & Ying, Q.-L. Derivation and propagation of embryonic stem cells in serum- and feeder-free culture. in *Embryonic Stem Cell Protocols* (ed. Turksen, K.) vol. 329 91–98 (Humana Press, 2006).
56. Ran, F. A. *et al.* Genome engineering using the CRISPR-Cas9 system. *Nat. Protocols* 8, 2281–2308 (2013).
57. Rahimoff, R. *et al.* 5-Formyl- and 5-Carboxydeoxycytidines Do Not Cause Accumulation of Harmful Repair Intermediates in Stem Cells. *J. Am. Chem. Soc.* 139, 10359–10364 (2017).
58. Weiner, K. X., Weiner, R. S., Maley, F. & Maley, G. F. Primary structure of human deoxyctydylate deaminase and overexpression of its functional protein in Escherichia coli. *J. Biol. Chem.* 268, 12983–12989 (1993).
59. Traube, F. R. *et al.* Isotope-dilution mass spectrometry for exact quantification of noncanonical DNA nucleosides. *Nature Protocols* 14, 283 (2019).

**Acknowledgements**
We are very thankful to the following colleagues: Markus Möser (Max Planck Institute for Biochemistry, Martinsried, Germany) for K3 mPSCs (Kindlin3+/+); Hitoshi Niwa and Masaki Okano (both at Kumamoto University, Japan) for Oct4-YFP-Puro mPSCs and Dnmt TKO J1, respectively; Yi Zhang (Boston Children’s Hospital, Boston, MA) for parental and Tet TKO E14tg2a. Anti-DCTD antibody and purified recombinant DCTD protein were generous gifts from Frank Maley (New York State University, NY).
Funding was provided by the Deutsche Forschungsgemeinschaft via the programs SFB1309 (TP: A4), SFB1361 (TP: 2), GRK 2338 and SPP-1784. This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement n° EPiR 741912). YZ is supported by the China Scholarship Council (CSC Nr. 201806200069).

**Author Contributions**

FS and TC conceived the study and designed experiments. FS, SS, AK, YZ, OK and JS performed experiments and analyzed data. FS, TC and SS interpreted data. RR, CE and EK synthesized isotopically labelled nucleosides used as standards for LC-MS/MS. FS, TC and SS wrote the manuscript.

**Competing interests**

The authors declare no competing interests.

**Data availability and code availability statements**

The data that support the findings of this study are available from the corresponding authors upon reasonable request.
References

1. Greenberg, M. V. C. & Bourc'his, D. The diverse roles of DNA methylation in mammalian development and disease. Nat Rev Mol Cell Biol 1–18 (2019) doi:10.1038/s41580-019-0159-6.
2. Luo, C., Hajkova, P. & Ecker, J. R. Dynamic DNA methylation: In the right place at the right time. Science 361, 1336–1340 (2018).
3. Jeltsch, A. & Jurkowska, R. Z. Allosteric control of mammalian DNA methyltransferases – a new regulatory paradigm. Nucl. Acids Res. 44, 8556–8575 (2016).
4. He, Y. & Ecker, J. R. Non-CG Methylation in the Human Genome. Annual Review of Genomics and Human Genetics 16, 55–77 (2015).
5. Tahiliani, M. et al. Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1. Science 324, 930–935 (2009).
6. Ito, S. et al. Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine. Science 333, 1303–1307 (2011).
7. He, Y.-F. et al. Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA. Science 333, 1303–1307 (2011).
8. Spruijt, C. G. et al. Dynamic Readers for 5-(Hydroxy)Methylcytosine and Its Oxidized Derivatives. Cell 152, 1146–1159 (2013).
9. Bochtler, M., Kolano, A. & Xu, G.-L. DNA demethylation pathways: Additional players and regulators. BioEssays n/a-n/a (2016) doi:10.1002/bies.201600178.
10. Schuermann, D., Weber, A. R. & Schär, P. Active DNA demethylation by DNA repair: Facts and uncertainties. DNA Repair 44, 92–102 (2016).
11. Wu, X. & Zhang, Y. TET-mediated active DNA demethylation: mechanism, function and beyond. Nat Rev Genet 18, 517–534 (2017).
12. Schomacher, L. et al. Neil DNA glycosylases promote substrate turnover by Tdg during DNA demethylation. Nature Structural & Molecular Biology 23, 116–124 (2016).
13. Schomacher, L. & Niehrs, C. DNA repair and erasure of 5-methylcytosine in vertebrates. BioEssays n/a-n/a (2017) doi:10.1002/bies.201600218.
14. Chen, C.-C., Wang, K.-Y. & Shen, C.-K. J. The Mammalian de novo DNA Methyltransferases Dnmt3a and Dnmt3b Are Also DNA 5-Hydroxymethyl Cytosine Dehydroxymethylases. J. Biol. Chem. 287, 33116–33121 (2012).
15. Liutkevičiūtė, Z., Lukinavičius, G., Masevičius, V., Daujotytė, D. & Klimašauskas, S. Cytosine-5-methyltransferases add aldehydes to DNA. Nature Chemical Biology 5, 400–402 (2009).
16. Schiesser, S. et al. Mechanism and Stem-Cell Activity of 5-Carboxycytosine Decarboxylation Determined by Isotope Tracing. Angewandte Chemie International Edition 51, 6516–6520 (2012).
17. Metivier, R. et al. Cyclical DNA methylation of a transcriptionally active promoter. Nature 452, 45–50 (2008).
18. Cortellino, S. et al. Thymine DNA Glycosylase Is Essential for Active DNA Demethylation by Linked Deamination-Base Excision Repair. Cell 146, 67–79 (2011).
19. Rai, K. et al. DNA Demethylation in Zebrafish Involves the Coupling of a Deaminase, a Glycosylase, and Gadd45. Cell 135, 1201–1212 (2008).
20. Grün, I. & Ishchenko, A. A. An interplay of the base excision repair and mismatch repair pathways in active DNA demethylation. Nucl. Acids Res. 44, 3713–3727 (2016).
21. Franchini, D.-M. et al. Processive DNA Demethylation via DNA Deaminase-Induced Lesion Resolution. PLoS ONE 9, e97754 (2014).
22. Santos, F. et al. Active demethylation in mouse zygotes involves cytosine deamination and base excision repair. Epigenetics & Chromatin 6, 39 (2013).
23. Atlasi, Y. & Stunnenberg, H. G. The interplay of epigenetic marks during stem cell differentiation and development. Nature Reviews Genetics 18, 643–658 (2017).
24. Singer, Z. S. et al. Dynamic Heterogeneity and DNA Methylation in Embryonic Stem Cells. Molecular Cell 55, 319–331 (2014).
25. Habibi, E. et al. Whole-Genome Bisulfite Sequencing of Two Distinct Interconvertible DNA Methylomes of Mouse Embryonic Stem Cells. Cell Stem Cell 13, (2013).
28. von Meyenn, F. et al. Impairment of DNA Methylation Maintenance Is the Main Cause of Global Demethylation in Naive Embryonic Stem Cells. *Molecular Cell* 62, 848–861 (2016).
29. Toyooka, Y., Shimosato, D., Murakami, K., Takahashi, K. & Niwa, H. Identification and characterization of subpopulations in undifferentiated ES cell culture. *Development* 135, 909–918 (2008).
30. Kim, H. et al. Modulation of β-catenin function maintains mouse epiblast stem cell and human embryonic stem cell self-renewal. *Nat Commun* 4, 2403 (2013).
31. Pfaffeneder, T. et al. Tet oxidizes thymine to 5-hydroxymethyluracil in mouse embryonic stem cell DNA. *Nat Chem Biol* 10, 574–581 (2014).
32. Shirane, K. et al. Global Landscape and Regulatory Principles of DNA Methylation Reprogramming for Germ Cell Specification by Mouse Pluripotent Stem Cells. *Developmental Cell* 39, 87–103 (2016).
33. Blaschke, K. et al. Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. *Nature* 500, 222–226 (2013).
34. van Mierlo, G., Wester, R. A. & Marks, H. A mass spectrometry survey of chromatin-associated proteins in pluripotency and early lineage commitment. *Proteomics* AOP (2019) doi:10.1002/pmic.201900047.
35. Yagi, M. et al. Derivation of ground-state female ES cells maintaining gamete-derived DNA methylation. *Nature* 548, 224–227 (2017).
36. Choi, J. et al. Prolonged Mek1/2 suppression impairs the developmental potential of embryonic stem cells. *Nature* 548, 219–223 (2017).
37. Kalkan, T. et al. Tracking the embryonic stem cell transition from ground state pluripotency. *Development* 144, 1221–1234 (2017).
38. Lu, F., Liu, Y., Jiang, L., Yamaguchi, S. & Zhang, Y. Role of Tet proteins in enhancer activity and telomere elongation. *Genes Dev.* 28, 2103–2119 (2014).
39. Hooper, M., Hardy, K., Handyside, A., Hunter, S. & Monk, M. HPRT-deficient (Lesch–Nyhan) mouse embryos derived from germline colonization by cultured cells. *Nature* 326, 292–295 (1987).
40. Tsumura, A. et al. Maintenance of self-renewal ability of mouse embryonic stem cells in the absence of DNA methyltransferases Dnmt1, Dnmt3a and Dnmt3b. *Genes Cells* 11, 805–14 (2006).
41. Jekunen, A., Puukka, M. & Vilpo, J. Exclusion of exogenous 5-methyl-2'-deoxycytidine from DNA in human leukemic cells: A study with [2-14C]- and [methyl-14C]5-methyl-2'-deoxycytidine. *Biochemical Pharmacology* 32, 1165–1168 (1983).
42. Maley, G. F., Lobo, A. P. & Maley, F. Properties of an affinity-column-purified human deoxycytidylate deaminase. *Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology* 1162, 161–170 (1993).
43. de Saint Vincent, B. R., Déchamps, M. & Buttin, G. The modulation of the thymidine triphosphate pool of Chinese hamster cells by dCMP deaminase and UDP reductase. Thymidine auxotrophy induced by CTP in dCMP deaminase-deficient lines. *J. Biol. Chem.* 255, 162–167 (1980).
44. Shen, J.-C., Rideout, W. M. & Jones, P. A. The rate of hydrolytic deamination of 5-methylcytosine in double-stranded DNA. *Nucl. Acids Res.* 22, 972–976 (1994).
45. Shipony, Z. et al. Dynamic and static maintenance of epigenetic memory in pluripotent and somatic cells. *Nature* 513, 115–119 (2014).
46. Ooi, S. K. et al. Dynamic instability of genomic methylation patterns in pluripotent stem cells. *Epigenetics & Chromatin* 3, 17 (2010).
47. Chen, T., Ueda, Y., Dodge, J. E., Wang, Z. & Li, E. Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. *Mol Cell Biol* 23, 5594–605 (2003).
48. Bachman, M. et al. 5-Hydroxymethylcytosine is a predominantly stable DNA modification. *Nat Chem* 6, 1049–1055 (2014).
49. Bachman, M. et al. 5-Formylcytosine can be a stable DNA modification in mammals. *Nat Chem Biol* 11, 555–557 (2015).
50. Tichy, E. D. et al. Mouse Embryonic Stem Cells, but Not Somatic Cells, Predominantly Use Homologous Recombination to Repair Double-Strand DNA Breaks. *Stem Cells and Development* 19, 1699–1711 (2010).
51. Tichy, E. D. et al. Mismatch and base excision repair proficiency in murine embryonic stem cells. *DNA Repair* 10, 445–451 (2011).
52. Maynard, S. et al. Human Embryonic Stem Cells Have Enhanced Repair of Multiple Forms of DNA Damage. *STEM CELLS* 26, 2266–2274 (2008).
Figure Legends

**Figure 1. Drastic reduction of global genomic mdC oxidation and increase of mdC to mdU conversion upon transition to primed pluripotency.**

a) Proposed de-modification pathways for genomic C5-cytosine modifications and expected labelled mdC derivatives upon metabolic labelling with m+4Met. b) Nucleoside isotopologues used as internal standards for UHPLC-MS$^3$ analysis. Black balls in the ribose represent $^{13}$C atoms. c and d) Time course analysis of genomic dC derivatives upon metabolic labelling with m+4Met under naïve (c; a2i/LIF) and priming (d; CHIR/IWR1) conditions. The labelling/time course schedules are shown at the top. Global levels of unlabelled (pale yellow) mdC and m+4dC (dark yellow), hm+3C (blue) and f+2C (green) are shown as mean and standard deviation of three technical replicates. See also Fig. S3 for an independent biological replicate. LOD = limit of detection.

**Figure 2. Turnover of genomic mdC and its derivatives under naïve and priming conditions**

a) Workflow of m+4Met and dT+12 pulse-chase experiments with wild type mPSCs under naïve and priming conditions. b) Global profiles of the indicated labelled cytosine derivatives and dT+12 in the genome of naïve (a2i/LIF; left) and primed mPSCs (CHIR/IWR1; right and inset) upon chase of m+4Met. Upper panels show values relative to the highest level for each modification. Dashed lines represent first order decay fitted curves. Lower panels show absolute values of genomic m+4Met (note the different scales for m+4dU in the two conditions). Mean values and standard deviation of triplicate measurements are shown. c) Percent of difference between fold changes of dT+12 and m+4dC in wt mPSCs under priming conditions. Shown are mean and standard deviation of three independent biological replicates.

**Figure 3. The active component of mdC turnover in primed pluripotent cells largely depends on Tet proteins.**

m+4Met and dT+12 pulse-chase experiment with parental and Tet TKO E14tg2a mPSCs under priming conditions (CHIR/IWR1). Profiles of global genomic levels of the indicated labelled cytosine derivatives and dT+12 are shown. Upper and mid panels show m+4dC and dT+12 values relative to the highest data point for each modification. Upper panels display magnifications of mid panels fields in dotted frames. Dashed lines represent first order decay fitted curves.
Figure 4. All detectable mdC deamination takes place in the soluble pool after DNA repair.

a) Potential pathways for the conversion of genomic m+4dC into genomic m+4dU. b) wt mPSCs were primed under CHIR/IWR1 conditions in the presence of m+4Met and growing concentrations of unlabelled dT in the culture medium as indicated. c) wt and CD-DKO clones mPSCs were grown under serum/LIF conditions in the presence of m+4Met. d) wt and CD-DKO clone #40 mPSCs were metabolically labelled with m+4Met under CHIR/IWR1 priming conditions. In b-d priming and labelling was for five days. Global genomic contents of mdC, m+4dC (upper panels) and m+4dU (lower panels) are shown as mean and standard deviation of three technical replicates. LOD = limit of detection.

Figure 5. mdC turnover through oxidation-independent DNA repair is developmentally regulated.

a) Cultures of mPSCs in naïve (a2iL = a2i/LIF) and primed states (CR = CHIR/IWR1; FA = FGF-2/Activin A; CDM = Chemically Defined Medium), primary (pmEFs) and immortalized mouse embryonic fibroblasts (imEFs and NIH3T3), HeLa and mPSC-derived neural stem cells (mNSCs) were labelled for the indicated number of days (d) with m+4Met. Asterisks indicate cases where distinct parallel cultures in the absence and presence of m+4Met were used to measure global levels of genomic mdC and m+4dU, respectively. In all other cases mdC, m+4dC and m+4dU were measure in the same culture labelled with m+4Met. Mean and standard deviation of three technical replicates are shown. b) Schematic summary of the dC modification turnover pathways identified in primed pluripotent cells. Deamination of genomic mdC followed by BER could not be detected and may occur only at levels below the sensitivity of our assay.
Figure 1

a. Metabolic labelling with \[^{13}C_2,^{15}N_2\]-methyl-methionine (alias \[^{m+4}\]-Met)

\[ \text{D}_{\text{D}} \text{D}_{\text{D}} \text{D}_{\text{OH}} \text{NH}_2 \text{CD}_3 \text{NH}_2 \text{D}_{\text{O}} \text{D}_{\text{O}} \text{N} \text{D}_{\text{OH}} \text{N} \text{D}_{\text{OH}} \text{D}_{\text{O}} \text{D}_{\text{O}} \text{D}_{\text{OH}} \text{NH}_2 \]

\[ \rightarrow \text{UHPLC-MS/MS analysis} \]

Dilution

C-C Bond Cleavage

Oxidative Pathway

Deamination

~0.06% of hmc

Base Excision Repair

b. [\[^{D}_{\text{D}},^{N}_{\text{N}}\]-mdC]

[\[^{13}C_2,^{15}N_2\]-hmC]

[\[^{13}C_2,^{15}N_2\]-fdC]

[\[^{13}C_2,^{15}N_2\]-dT]

c. a2i/LIF

0 12 24 36 48 hours m+4Met

m-4C-6C4N3 [x 10^7]

0 12 24 36 48 h

m-4C-6C4N3 [x 10^7]

0 12 24 36 48 h

m-4C-6C4N3 [x 10^7]

0 12 24 36 48 h

m-4C-6C4N3 [x 10^7]

0 12 24 36 48 h

d. CHIR/IWR1

0 1 2 3 0 12 24 32 48 hours m+4Met

m-4C-6C4N3 [x 10^7]

0 12 24 36 48 h

m-4C-6C4N3 [x 10^7]

0 12 24 36 48 h

m-4C-6C4N3 [x 10^7]

0 12 24 36 48 h

m-4C-6C4N3 [x 10^7]

0 12 24 36 48 h

m-4C-6C4N3 [x 10^7]

0 12 24 36 48 h
Figure 2

a) A timeline diagram showing the passage and chase periods with different treatments.

b) Graphs showing fold change over time for treatments in a2i/LIF and CHIR/IWR1 conditions.

C) Graphs showing the change in fold change for treatments in CHIR/IWR1 conditions.
Figure 3

E14tg2a

Tet TKO E14tg2a

fold change

fold change

m+4dC

dT+12
Figure 5

(a) Bar graph showing modification/dN [x10^3] for mdC and m+4dC in various cell types.

(b) Diagram illustrating DNA repair and C-C bond cleavage with dilution and direct repair pathways.

DNA repair/C-C bond cleavage: ~5%

Dilution

NH₂

\( \text{C:G} \) → \( \text{C:G} \) → \( \text{C:G} \) → \( \text{C:G} \)

R = CH₂OH
CHO
COOH
R' = H, PO₃

Germinotropic stimulation

Direct repair: <1%

\( \text{mU:G} \) → \( \text{d₄C(MP)} \) → \( \text{d₄U(MP)} \) → \( \text{mU:A} \)